Clear All
785 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
C1086 Temozolomide Temodar 5 mg Chemotherapy Alkylating Agent Tetrazine Yes 1999 Jan 1, 2010 In Use
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
Q0167 Dronabinol Marinol 2.5 mg Ancillary Therapy Antiemetic CB1/CB2 Yes 1985 Apr 1, 1998 In Use
NA Cabozantinib Cabometyx 60 mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2012 In Use
NA Mitotane Lysodren unspecified Chemotherapy Miscellaneous Agent Adrenal Suppressant Yes 1970 In Use
J9206 Irinotecan Camptosar 20 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 1998 In Use
J8650 Nabilone Cesamet 1 mg Ancillary Therapy Antiemetic Cannabinoid Yes 1985 Jan 1, 2007 In Use
NA Pomalidomide Pomalyst 1 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
NA Capmatinib Tabrecta 150mg, 200mg Chemotherapy Tyrosine Kinase Inhibitor MET Yes 2020 In Use
Q5114 Trastuzumab-dkst Ogivri 10mg Immunotherapy Monoclonal Antibody HER2 No 2017 Jul 1, 2019 In Use
NA Crizotinib Xalkori 200 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2011 In Use
J1380 Estradiol Valerate Delestrogen 10 mg Hormonal Therapy Estrogen No 1954 Jan 1, 1997 In Use
J0870 Imetelstat Rytelo 1mg Chemotherapy Enzyme Inhibitor Telomerase No 2024 Dec 17, 2024 In Use
NA Dasatinib Sprycel 50 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J9600 Porfimer Photofrin 75 mg Chemotherapy Photosensitizing Agent Cytotoxin No 1995 Jan 1, 1998 In Use
NA Pomalidomide Pomalyst 2 mg Immunotherapy Immunomodulator Thalidomide Analog Yes 2013 In Use
J9326 Telisotuzumab vedotin-tllv Emrelis 1mg Immunotherapy Drug Antibody Conjugate c-MET No 2025 Jan 12, 2026 In Use
J8670 Rolapitant Varubi 1 mg Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Yes 2015 Jan 1, 2017 In Use
J9308 Ramucirumab Cyramza 5mg Immunotherapy Monoclonal Antibody VEGFR No 2014 Jan 1, 2016 In Use
NA Estradiol Estrace 1 mg Hormonal Therapy Estrogen Yes 1998 In Use
Q2055 Idecabtagene vicleucel Abecma 460 million Immunotherapy CAR-T BCMA No 2021 Jan 26, 2022 In Use
J9356 Trastuzumab and Hyaluronidase-oysk Herceptin hylecta 10mg Immunotherapy Monoclonal Antibody HER2 No 2019 Jul 1, 2019 In Use
J1448 Trilaciclib Cosela 1mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 No 2021 Sep 27, 2021 In Use
NA Trametinib Mekinist 0.5 mg Chemotherapy MEK Inhibitor BRAF Yes 2013 In Use
NA Dabrafenib Tafinlar 75 mg Chemotherapy Tyrosine Kinase Inhibitor BRAF Yes 2013 Jan 1, 2004 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.